| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | FIMM | pan-cancer | AAC | -0.28 | 0.08 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.056 | 0.09 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.057 | 0.09 |
| mRNA | SGC0946 | GDSC1000 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | MS-275 | FIMM | pan-cancer | AAC | -0.22 | 0.1 |
| mRNA | oligomycin a | CTRPv2 | pan-cancer | AAC | -0.059 | 0.1 |
| mRNA | lenalidomide | FIMM | pan-cancer | AAC | -0.27 | 0.1 |
| mRNA | BX-912 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.1 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.05 | 0.1 |